Latest Allotransplantation Stories

CENTENNIAL, Colo., Sept. 22, 2011 /PRNewswire/ -- AlloSource, a leading developer, processor and distributor of bone and soft-tissue allografts for use in surgical procedures around the world, today announced that Executive Vice President Kevin Cmunt has been selected as the next President-Elect of the nonprofit American Association of Tissue Banks, (AATB), the definitive source on safety and standards in the tissue banking industry. Cmunt will assume his role of President-Elect at the...

CENTENNIAL, Colo., Aug. 9, 2011 /PRNewswire/ -- AlloSource, a leading developer, processor and distributor of bone and soft-tissue allografts for use in surgical procedures around the world, today announced two new key affiliations with the Alliance for Regenerative Medicine (ARM) and the Medical Device Manufacturers Association (MDMA). AlloSource pursued membership with both organizations in order to support medical device and regenerative medicine grassroots efforts with policy makers....

(Ivanhoe Newswire) -- New research finds that growing blood stem cells in the laboratory for about a week may help to overcome one of the most difficult roadblocks to successful transplantation, immune rejection. The study may lead to more promising therapeutic strategies for transplanting blood stem cells.Hematopoietic stem cells (HSCs) are cells that can give rise to all of the different types of blood cells. Transplantation of HSCs has been used to treat leukemia, lymphoma, and other types...

BELGRADE, Mont., Aug. 5, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and anti-infective coatings for medical applications, achieved its most productive processing month in July. The record month reflects both greater capacity and efficiency in the company's operational platform, which is largely due to several new hires and a management reorganization completed during the month. "As our first...

New research finds that growing blood stem cells in the laboratory for about a week may help to overcome one of the most difficult roadblocks to successful transplantation, immune rejection. The study, published by Cell Press in the August issue of the journal Cell Stem Cell, may lead to more promising therapeutic strategies for transplanting blood stem cells.Hematopoietic stem cells (HSCs) are cells that can give rise to all of the different types of blood cells. Transplantation of HSCs has...

CENTENNIAL, Colo., July 28, 2011 /PRNewswire/ -- AllograftPossibilities.org has rapidly grown into the premier source for straightforward information on tissue donation and transplant on the web. Although it has the same life-saving and life-enhancing benefits of organ donation, tissue donation is still lesser understood by the general public. The nonprofit AlloSource, a leading developer, processor, and distributor of bone and soft-tissue allografts for use in surgical procedures around...

(Ivanhoe Newswire) "“ Avoiding kidney mismatching is beneficial in pediatric kidney transplant patients, however, the likelihood of finding a matching donor must be considered against the wait time for a possible donation, according to this study."Although avoiding HLA [human leukocyte antigen; cell surface antigens that regulate host cell responses to transplanted cells] antigen mismatching has been shown to benefit long-term graft survival, it has raised concerns about disadvantaging...

Avoiding HLA-DR mismatching appears to be beneficial in pediatric kidney transplant patients, however the likelihood of finding a matching donor must be considered against the wait time for a possible donation, according to a report in the July issue of Archives of Surgery, one of the JAMA/Archives journals."Although avoiding HLA [human leukocyte antigen; cell surface antigens that regulate host cell responses to transplanted cells] antigen mismatching has been shown to benefit long-term...

LOS ANGELES, July 15, 2011 /PRNewswire-USNewswire/ -- In a major step into a new transplantation frontier, UCLA has established a first-of-its-kind program to restore functionality and enhance quality of life for people who have suffered severe trauma or other disfiguring injuries to the upper extremities, face or abdomen. The UCLA Section of Reconstructive Transplantation represents a multidisciplinary effort to use a new transplantation approach known as vascularized composite...

MELBOURNE, Australia, July 7, 2011 /PRNewswire/ -- Key points: Mesoblast's first Phase 3 trial submission cleared by United States Food and Drug Administration (FDA)Rapid clearance (within 30 days) further validation of Mesoblast's clinical, regulatory, and manufacturing capabilitiesMesoblast's proprietary adult stem cells expand hematopoietic precursor cells in umbilical cord blood 40-fold, enabling rapid bone marrow reconstitution with lowered risk of life-threatening Graft Versus Host...